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Microabstract 
We assessed outcomes from men with metastatic castration-resistant prostate cancer that 
had spread to the liver and/or lungs in the PREVAIL clinical trial of enzalutamide in patients 
who had not received docetaxel chemotherapy. Compared with placebo, enzalutamide 
lengthened the time it took for the cancers to grow (according to changes in scans), 
prostate-specific antigen to rise, or patients to require chemotherapy. 
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Abstract 
Purpose: The placebo-controlled PREVAIL trial of the oral androgen-receptor inhibitor 
enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer 
(mCRPC) was unique as it included patients with visceral disease. This analysis was 
designed to describe outcomes for the subgroup of men from PREVAIL with specific sites of 
visceral disease to help clinicians understand how these patients responded to enzalutamide 
prior to chemotherapy.  
Patients and Methods: Prespecified analyses examined the coprimary endpoints of 
radiographic progression-free survival (rPFS) and overall survival (OS) only. All other 
efficacy analyses were post hoc. The visceral subgroup was divided into liver or lung 
subsets. Patients with both liver and lung metastases were included in the liver subset.  
Results: Of the 1717 patients in PREVAIL, 204 (12%) had visceral metastases at screening 
(liver only or liver/lung metastases, n = 74; lung only metastases, n = 130). In patients with 
liver metastases, enzalutamide was associated with an improvement in rPFS (hazard ratio 
[HR], 0.44; 95% confidence interval [CI], 0.22-0.90) but not OS (HR, 1.04; 95% CI, 0.57-
1.87). In patients with lung metastases only, the HR for rPFS (0.14; 95% CI, 0.06-0.36) and 
OS HR (0.59; 95% CI, 0.33-1.06) favored enzalutamide over placebo. Patients with liver 
metastases had worse outcomes than those with lung metastases, regardless of treatment. 
Enzalutamide was well tolerated in patients with visceral disease.   
Conclusions: Enzalutamide is an active first-line treatment option for men with 
asymptomatic or mildly symptomatic chemotherapy-naïve mCRPC and visceral disease. 
Patients with lung-only disease fared better than patients with liver disease, regardless of 
treatment. 
 
ClinicalTrials.gov number: NCT01212991 
Keywords: androgen receptor inhibitor; survival analysis; chemotherapy-naïve; phase III 
Abbreviations: AE = adverse event; CRPC = castration-resistant prostate cancer; CI = 
confidence interval; ECOG PS = Eastern Cooperative Oncology Group Performance Status; 
FACT-P = Functional Assessment of Cancer Therapy–Prostate questionnaire; HR = hazard 
ratio; IQR = interquartile range; mCRPC = metastatic castration-resistant prostate cancer; 
NYR = not yet reached; OS = overall survival; PSA = prostate-specific antigen; rPFS = 
radiographic progression-free survival.  
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Introduction 
Nearly all patients with recurrent prostate cancer or de novo metastatic disease treated with 
androgen deprivation therapy eventually develop castration-resistant prostate cancer 
(CRPC), the lethal form of this disease.1,2 Survival of patients with metastatic CRPC 
(mCRPC) is usually < 3 years, with > 26,000 deaths predicted in the United States alone in 
2016.3-7 Patients with mCRPC with visceral disease, most commonly in liver and/or lung, are 
thought to have a particularly poor prognosis, and the presence of liver metastases is 
associated with the shortest survival.3,4,8,9   
During the drug development process, patients with mCRPC have been previously 
categorized by docetaxel chemotherapy exposure, the first drug to improve overall survival 
(OS) for men with mCRPC in phase III trials.10,11 Studies of systemic agents in the post-
docetaxel setting have generally included men with visceral disease.12-14 However, phase III 
trials in the pre-docetaxel setting have excluded these patients because of the widespread 
belief that docetaxel, rather than an investigational agent is the preferred treatment option for 
patients with visceral disease given their poor prognosis.15,16 The PREVAIL phase III trial of 
the oral androgen-receptor inhibitor enzalutamide versus placebo in men with asymptomatic 
or minimally symptomatic chemotherapy-naïve mCRPC challenged this view by enrolling 
patients with visceral disease, provided they were otherwise eligible based on performance 
criteria (ie, an Eastern Cooperative Oncology Group Performance Status [ECOG PS] of 0 or 
1 and a score of 0-3 on Brief Pain Inventory Short Form question 3).5 PREVAIL was 
designed with the expectation that minimally symptomatic men with good ECOG PS would 
be followed carefully with imaging studies and could receive an investigational therapy or 
placebo and still receive chemotherapy after discontinuing the study medication.  
In PREVAIL, enzalutamide significantly improved OS and radiographic progression-free 
survival (rPFS) relative to placebo in the overall population of men with chemotherapy-naïve 
mCRPC.5 A prespecified subgroup analysis of PREVAIL data revealed that treatment with 
enzalutamide reduced the risk of the composite endpoint of radiographic progression or 
death by 72% (hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.16-0.49) but not risk 
of death (HR, 0.82; 95% CI, 0.55-1.23) in patients with visceral disease, defined as a 
combined population with baseline disease in the liver and/or lung, with or without 
metastases to the bone or lymph nodes.17 Outcomes for patients with lymph node–only 
disease were also analyzed in this subgroup analysis.17 The current analysis of PREVAIL 
determines how outcomes with enzalutamide versus placebo treatment were affected by the 
specific site of visceral disease (ie, liver metastases vs. lung-only metastases). Moreover, 
this analysis provides information on the natural history of chemotherapy-naïve patients with 
mCRPC and liver or lung-only visceral disease treated in the placebo arm. 
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Patients and Methods 
Study Design and Participants   
The PREVAIL study design, eligibility criteria, and conduct have been fully described 
elsewhere.5 Patients were randomized to either oral enzalutamide 160 mg/day or placebo 
until the occurrence of unacceptable adverse events, or confirmed radiographic progression 
and the initiation of chemotherapy or an investigational agent. The study was approved by 
the independent review board at each participating site, and was conducted in compliance 
with the ethical principles originating in or derived from the provisions of the Declaration of 
Helsinki and the Good Clinical Practice Guidelines of the International Conference on 
Harmonisation. All patients provided written informed consent before participating in the trial.  
Presence of visceral disease (liver and/or lung) was determined radiographically (computed 
tomography scan or magnetic resonance imaging) by the treating physician and did not 
require confirmation by biopsy. For all efficacy analyses, the visceral subgroup was divided 
into liver and lung subsets. Patients with both liver and lung metastases were included in the 
liver subset because of the previously described inferior survival outcomes of patients with 
liver versus lung-only involvement.3,4,8,9   
The coprimary endpoints of rPFS and OS were prospectively evaluated in the liver and lung 
subsets along with the exploratory analysis of the following endpoints (all were secondary 
endpoints in PREVAIL except where indicated): time to initiation of chemotherapy, time to 
prostate-specific antigen (PSA) progression, time to decline on the Functional Assessment 
of Cancer Therapy–Prostate questionnaire (FACT-P; exploratory endpoint), confirmed PSA 
response (≥ 50% PSA decline from baseline), and best overall tissue response determined 
by investigator assessment using Response Evaluation Criteria In Solid Tumors version 1.1. 
The coprimary endpoint rPFS was defined as time from randomization to first objective 
evidence of radiographic disease progression assessed by a blinded independent central 
review facility or death from any cause within 168 days after treatment discontinuation, 
whichever occurred first. 
Statistical Analysis 
The Kaplan-Meier product limit method was used to estimate distributions of the time to 
events. Hazard ratios and their 95% CIs were estimated using an unstratified Cox regression 
model. A two-sided, unstratified log-rank test was used to compare rPFS and OS between 
enzalutamide and placebo. The primary analysis was by intention-to-treat, defined as those 
8 
 
 
 
patients with measurable disease at screening who were then randomized to one of the 
treatment arms. 
Cochran-Mantel-Haenszel score tests were used to compare the proportion of enzalutamide- 
and placebo-treated patients with a confirmed ≥ 50% reduction in PSA from baseline to PSA 
nadir and objective response, with corresponding two-sided 95% CIs calculated using the 
Clopper-Pearson method. 
Incidence data were used to assess the safety and tolerability of enzalutamide and placebo. 
To adjust for differences in duration of study treatment between the enzalutamide and 
placebo groups, adverse events (AEs) were also evaluated using event-rate calculations 
(events per 100 patient-years). 
The results presented herein are based on a cutoff date of September 16, 2013, except for 
rPFS, which was based on a data cutoff date of May 6, 2012. 
 
Results 
Patients and Treatment 
In PREVAIL, 1717 patients were randomized to treatment: 872 to enzalutamide and 845 to 
placebo (Figure A1, appendix). Overall, 204 patients had visceral disease at baseline: 98 
(11%) in the enzalutamide group and 106 (13%) in the placebo group (Table 1). Among 
patients with visceral disease, liver metastases (in 36% of patients) were less frequent than 
lung metastases (in 64% of patients). Six patients (0.7%) in the enzalutamide group and 
three (0.4%) in the placebo group had both liver and lung metastases and were included in 
the liver subset.  
In the visceral subgroup, patient demographics and disease characteristics were generally 
similar between treatment arms (Table 1). Liver and lung subsets were well balanced 
between each other and the full population with respect to patient age, ECOG PS, median 
Gleason score, baseline levels of hemoglobin and albumin, baseline pain, and presence of 
bone disease. A greater proportion of patients in the liver subset than those in the lung 
subset and full population had more than 20 bone metastases (Table 1). Patients with liver 
metastases also had higher baseline levels of lactate dehydrogenase, alkaline phosphatase, 
and PSA than those with lung metastases and those in the full population. 
In both the liver and lung subsets, duration of treatment was longer with enzalutamide than 
placebo (Table 2). However, duration of enzalutamide and placebo treatment was shorter in 
the liver subset than the lung subset and full population.  
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Efficacy 
Coprimary endpoints  
Treatment with enzalutamide versus placebo reduced the risk of radiographic progression or 
death by 56% in patients with liver metastases and by 86% in patients with lung metastases 
(Figure 1). The HR in the lung subset (0.14) was similar to that in the full population (0.19).5 
The HR in the smaller subset of patients with liver metastases favored enzalutamide (0.44), 
although the magnitude of benefit was less than in the lung subset or the full population. In 
both treatment groups, median rPFS was shorter in patients with liver metastases than in 
those with lung metastases.  
Treatment with enzalutamide versus placebo was not associated with a reduced risk of 
death in the subsets of patients with liver and/or lung metastases (Figure 2). In the liver 
subset, median OS was 18.9 months (interquartile range [IQR], 10.7-26.2) with enzalutamide 
and 14.8 months (IQR, 8.9-not yet reached [NYR]) with placebo, both considerably shorter 
than that observed in either the lung subset or full population.5 Median OS with enzalutamide 
in the lung subset (32.4 months; IQR, 20.9-NYR) was identical to that of patients in the full 
population receiving enzalutamide (32.4 months; IQR, 22.0-NYR5), and indicated some 
improvement in median OS over placebo (26.0 months; IQR, 14.8-NYR) in this subset of 
patients. 
A post hoc test of the interaction between treatment and visceral status was not significant 
for rPFS (P = .2231) or OS (P = .4755).  
Secondary and exploratory endpoints  
In both the liver and lung subsets, treatment with enzalutamide versus placebo was 
associated with improvements in all secondary endpoints (Figure 3), including delaying time 
to initiation of chemotherapy (by approximately 15 and 18 months, respectively), which was 
similar to that in the full population (approximate delay of 17 months). In both visceral 
subsets, treatment with enzalutamide was associated with delaying time to PSA progression. 
Confirmed PSA response rates (≥ 50% decline) with enzalutamide were 51% in the liver 
subset (0% with placebo) and 94% in the lung subset (3% with placebo). In the full 
population, PSA response rates were 78% with enzalutamide and 3% with placebo.5 The 
small subset of patients with liver metastases fared worse than those with lung metastases, 
who had benefits on secondary endpoints consistent with the full population. Enzalutamide 
did not delay time to FACT-P decline in the visceral subsets versus placebo, which was not 
the case in the full population.5 
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In patients with measurable disease at baseline, best overall soft-tissue response rate with 
enzalutamide was 29% (10 of 34 patients) in the liver subset and 73% (27 of 37 patients) in 
the lung subset and 3% (1 of 30 patients) and 0% (0 of 50 patients), respectively, with 
placebo. Six patients with visceral disease—two (6%) with liver metastases and four (11%) 
with lung metastases—achieved a complete response with enzalutamide. Radiographic 
images showing the disappearance of liver and lung lesions in two patients with a complete 
response to enzalutamide are shown in Figure A2 (appendix). 
Safety 
The incidence of any AE, grade 3 or 4 AEs, and serious AEs in the visceral subgroup were 
similar to those in the full study population (Table A1, appendix). The incidence rate of the 
most common AEs of fatigue, back pain, constipation, and arthralgia were each lower with 
enzalutamide than placebo; among specific AEs, rates of hypertension (11 vs. 8 per 100 
patient-years) and cardiac AEs (19 vs. 15 per 100 patient-years) were higher with 
enzalutamide, which was consistent with findings in the full population (Table A1, appendix).  
Subsequent Therapies 
More patients in the placebo arms of the nonvisceral and visceral subgroups received 
chemotherapy (either docetaxel or cabazitaxel) as the first subsequent therapy after 
progression (Table 3).  
 
Discussion 
The PREVAIL trial included patients with visceral disease who were asymptomatic or 
minimally symptomatic, had ECOG PS of 0 or 1, and were chemotherapy naïve. Men in the 
placebo arm also represent the first prospectively followed group with CRPC and visceral 
disease stratified by specific anatomical site to be reported.  
It is important for clinicians to understand how the subgroup of men with baseline visceral 
disease located at common sites of metastasis did with second-line hormone therapy prior to 
chemotherapy. A prior analysis showed that enzalutamide versus placebo reduced the risk 
of rPFS but not OS in the 204 PREVAIL patients with baseline visceral disease at any site.17 
Our analysis extends these findings by assessing enzalutamide efficacy specifically by the 
site of metastasis. Although patients with liver metastases had delayed radiographic 
progression and improvements on all progression and response endpoints, including 
complete responses in two (6%) patients, enzalutamide treatment did not improve OS in that 
subset. The lack of an effect on survival may have been because of the small number of 
patients with liver metastases in PREVAIL. 
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We focused on subsets of patients with liver and lung metastases because these were the 
most common sites of visceral disease, and we determined that these sites affected rPFS 
and OS, as well as secondary and exploratory endpoint measures. Patients with liver 
metastases had a distinctly worse outcome than those with lung metastases. Moreover, 
patients with lung-only visceral metastases had outcomes similar to patients without any 
visceral metastases and the overall PREVAIL study population.5 These findings confirm the 
poorer prognosis associated with liver metastases regardless of enzalutamide or placebo 
treatment, which is consistent with prior reports for other agents.3,4,8,9 We observed that a 
significant proportion of patients in the visceral and nonvisceral placebo arms were able to 
receive treatment with chemotherapy after progression on study, supporting the initial 
reasoning that placebo use in this population would not prevent subsequent treatment with 
chemotherapy. 
Our results suggest a need to better understand the underlying biology of metastatic tumors 
with a predilection to the liver that leads to inferior treatment responses and outcomes in 
CRPC patients regardless of the treatment prescribed. For those with lung-only metastases, 
improvements in rPFS, OS, and secondary endpoints were similar to those observed in the 
overall PREVAIL population. These findings suggest that the category of “visceral disease” 
should be divided into lung-only and liver and not analyzed separately, at least in this 
population of chemotherapy-naïve men with mCRPC. 
There is limited information on efficacy outcomes for chemotherapy-naïve mCRPC patients 
with visceral disease treated with systemic therapies other than chemotherapy. In the TAX 
327 study, docetaxel plus prednisone improved survival compared with mitoxantrone plus 
prednisone in men with mCRPC.10 An updated survival analysis that combined all patients 
who received chemotherapy in TAX 327 showed that patients with visceral disease (liver or 
lung sites not specified), who comprised 23% of the overall study population, died earlier 
than those without visceral disease.18 A subsequent retrospective analysis that evaluated 
outcomes by site of visceral disease showed PSA response rates of 22% and 31% in 
patients with liver or lung metastases and radiographic response rates of 6% and 7%, 
respectively.4 In comparison, patients with liver or lung metastases treated with 
enzalutamide in our analysis had PSA response rates of 51% and 94% and radiographic 
response rates of 29% and 73%, respectively. Complete responses were observed in 
individual patients with liver (6%) or lung (11%) metastases. Although the TAX 327 and 
PREVAIL trial populations and designs are not directly comparable and they were conducted 
more than a decade apart, our analysis suggests that enzalutamide has substantial clinical 
activity in chemotherapy-naïve patients with mCRPC with visceral disease, regardless of the 
site of visceral involvement.  
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Several strengths and limitations of our analysis should be noted. PREVAIL was the first 
phase III study of chemotherapy-naïve mCRPC men with minimal or no symptoms to include 
patients with visceral disease. Liver and lung subsets were prospectively defined in terms of 
number and sites of involvement as recommended by the Prostate Cancer Clinical Trials 
Working Group 2.19 However, because presence of visceral disease (liver and/or lung) was 
determined radiographically by the treating physician and did not require confirmation by 
biopsy, it is possible that some of the lesions were not accurately attributed. While 
enzalutamide was effective in chemotherapy-naïve mCRPC patients with visceral disease, it 
is likely that other agents that target androgen receptor signaling, such as abiraterone 
acetate, may also be efficacious. This assertion remains unresolved as the COU-302 study 
excluded men with visceral disease.15 Finally, the total number of patients with liver or lung 
metastases was small compared with the nonvisceral subgroup, and PREVAIL was not 
designed or powered to detect treatment differences within these subsets. Our 
interpretations of results must therefore be considered exploratory. 
 
Conclusions 
Our analysis has relevance for clinical practice by addressing a knowledge gap in the 
literature regarding the outcomes of men with asymptomatic or minimally symptomatic 
mCRPC and visceral disease involving the liver and/or lung who were treated with 
enzalutamide or placebo. Enzalutamide is a reasonable therapeutic option in such patients 
and appears to be well tolerated, with a safety profile similar to that observed in the full 
PREVAIL population. Because of the poorer outcomes in patients with liver metastases than 
in those with lung metastases observed in this and other studies,3,4,8,9 it is critical to identify 
tumor and microenvironment influences that may be responsible. Elucidating the biological 
differences between metastatic sites of CRPC may enable the development new drug 
combinations that further improve upon the efficacy of enzalutamide.  
 
Clinical Practice Points 
What is already known about this subject? Enzalutamide significantly decreases the risk 
of radiographic progression and death, delays the initiation of chemotherapy, and improves 
health-related quality of life in chemotherapy-naïve men with asymptomatic or minimally 
symptomatic metastatic prostate cancer progressing on androgen-deprivation therapy. 
What are the new findings? The PREVAIL trial of the oral androgen-receptor inhibitor 
enzalutamide versus placebo was unique in that it did not exclude patients with visceral 
13 
 
 
 
disease. Our analysis revealed that enzalutamide improved radiographic progression-free 
survival in patients with liver and/or lung disease.  
How might it impact on clinical practice in the foreseeable future? Enzalutamide may 
be considered to be an active first-line treatment option in patients with metastatic castration-
resistant prostate cancer, including those with visceral involvement, delaying the need for 
chemotherapy. 
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Appendix Captions 
Table A1. Summary of AEs in the PREVAIL visceral subgroup (liver and lung subsets 
combined) and full population. 
Figure A1. PREVAIL CONSORT diagram. 
Figure A2. Example of complete responses in metastatic castration-resistant prostate cancer 
patients with a (A) liver lesion and (B) lung lesion at baseline. 
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Figure Legends 
Figure 1 Kaplan-Meier Estimates of Radiographic Progression-Free Survival in 
Patients with Metastatic Castration-Resistant Prostate Cancer Who Participated in the 
Phase III PREVAIL Trial and Had Metastatic (A) Liver or (B) Lung Disease  
Abbreviations: CI = confidence interval; HR = hazard ratio; IQR = interquartile range; NYR = 
not yet reached. 
 
Figure 2 Kaplan-Meier Estimates of Overall Survival in Patients with Metastatic 
Castration-Resistant Prostate Cancer Who Participated in the Phase III PREVAIL Trial 
and Had Metastatic (A) Liver or (B) Lung Disease 
Abbreviations: CI = confidence interval; HR = hazard ratio; IQR = interquartile range; NYR = 
not yet reached. 
 
Figure 3 Secondary Efficacy Outcomes in the PREVAIL Visceral Subgroups and 
Full Population  
Abbreviations: chemo = chemotherapy; CI = confidence interval; ENZA = enzalutamide; 
FACT-P = Functional Assessment of Cancer Therapy–Prostate questionnaire; IQR = 
interquartile range; mets = metastases; NYR = not yet reached; PBO = placebo; PSA = 
prostate-specific antigen. 
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Table 1 Baseline Patient and Disease Characteristics in the PREVAIL Visceral Subgroups and Full Population 
Parameter 
Liver Metastases Lung Metastases Full Study Population 
Enzalutamide 
(n = 40) 
Placebo 
(n = 34) 
Enzalutamide 
(n = 58) 
Placebo 
(n = 72) 
Enzalutamide 
(n = 872) 
Placebo 
(n = 845) 
Age, median (IQR), years 74.0 (70.0-81.5) 70.0 (65.0-75.0) 73.0 (66.0-78.0) 71.0 (65.0-76.5) 72.0 (66.0-78.0) 71.0 (65.0-77.0) 
ECOG PS, n (%) 
0 22 (55) 23 (68) 37 (64) 44 (61) 584 (67) 585 (69) 
1 18 (45) 11 (32) 21 (36) 28 (39) 288 (33) 260 (31) 
Baseline pain score on BPI-SF Q3, n (%)
a
 
0-1 22 (56) 24 (73) 38 (66) 41 (57) 569 (66) 567 (68) 
≥ 2 17 (44) 9 (27) 20 (35) 31 (43) 290 (34) 273 (33) 
Median lactate dehydrogenase, U/L (IQR) 204.5 
(176.5-307.0) 
218.5 
(190.0-324.0) 
180.5 
(154.0-212.0) 
190.0 
(170.0-221.0) 
185.0 
(164.0-218.0) 
185.0 
(164.0-217.0) 
Median alkaline phosphatase, U/L (IQR) 112.0 
(77.5-168.0) 
126.5 
(77.0-298.0) 
91.5 
(71.0-119.0) 
89.0 
(70.0-131.0) 
94.0 
(70.0-138.0) 
86.0 
(68.0-126.0) 
Median PSA, ng/mL (IQR) 83.9 
(35.5-259.1) 
104.3 
(30.5-289.7) 
70.2 
(16.5-152.2) 
51.2 
(13.7-156.3) 
54.1 
(17.7-130.9) 
44.2 
(17.0-132.2) 
Median hemoglobin, g/L (IQR) 128.5 
(116.5-137.0) 
127.0 
(120.0-134.0) 
130.0 
(121.0-137.0) 
130.0 
(124.0-139.0) 
130.0 
(123.0-138.0) 
131.0 
(123.0-138.0) 
Table 1
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Median albumin, g/L (IQR) 37.5 
(36.0-41.5) 
37.0 
(35.0-39.0) 
39.0 
(36.0-41.0) 
38.0 
(36.0-40.0) 
38.0 
(36.0-40.0) 
39.0 
(36.0-40.0) 
Median Gleason score (IQR) 8.0 
(7.0-9.0) 
7.0 
(7.0-9.0) 
7.0 
(7.0-8.0) 
7.0 
(7.0-9.0) 
8.0 
(7.0-9.0) 
8.0 
(7.0-9.0) 
Gleason score ≥ 8 at initial diagnosis, n 
(%)
a
 
22 (56) 15 (47) 21 (38) 34 (49) 424 (51) 423 (52) 
Bone disease, n (%) 34 (85) 27 (79) 46 (79) 57 (79) 741 (85) 690 (82) 
      > 20 bone metastases, n (%) 10 (25) 13 (38) 7 (12) 14 (19) 145 (17) 150 (18) 
Measurable soft-tissue disease, n (%) 34 (85) 30 (88) 37 (64) 50 (69) 396 (45) 381 (45) 
Baseline use of corticosteroids, n (%) 3 (7.5) 2 (5.9) 3 (5.2) 2 (2.8) 35 (4.0) 36 (4.3) 
Prior antiandrogen use, n (%) 36 (90) 31 (91) 46 (79) 64 (89) 760 (87) 730 (86) 
Prior radical prostatectomy, n (%) 12 (30) 8 (24) 15 (26) 14 (19) 226 (26) 225 (27) 
Abbreviations: BPI-SF Q3 = Brief Pain Inventory Short Form question 3; ECOG PS = Eastern Cooperative Oncology Group Performance Status; IQR = 
interquartile range; PSA = prostate-specific antigen. 
a
Some patients had missing baseline values. Percentages were calculated based on all patients with baseline values.  
 
Table 2 Duration of Study Drug Treatment in the PREVAIL Visceral Subgroups and Full Population 
Parameter 
Liver Metastases Lung Metastases Full Study Population
a
 
Enzalutamide 
(n = 40) 
Placebo 
(n = 34) 
Enzalutamide 
(n = 58) 
Placebo 
(n = 72) 
Enzalutamide 
(n = 871) 
Placebo 
(n = 844) 
Duration of treatment, months 
Median (IQR) 9.6 (3.6-17.6) 3.4 (2.1-4.4) 15.5 (10.6-20.4) 3.9 (2.1-6.9) 16.6 (10.1-21.1) 4.6 (2.8-9.7) 
Mean (SD) 10.5 (8.15) 4.8 (4.67) 15.6 (8.21) 5.3 (4.32) 15.8 (7.64) 7.0 (6.05) 
Patients with ≥ 12 
months of 
treatment duration, % 
32 8.8 55 4.2 68 18 
Treatment ongoing at 
data cutoff date, % 
20 0 36 2.8 42 7.2 
Median OS follow-up, 
months (IQR) 
22.9 (17.4-27.2) 25.1 (20.5-27.8) 22.8 (18.2-29.2) 23.6 (20.9-27.5) 22.2 (18.5-26.7) 22.4 (18.5-26.4) 
Abbreviations: IQR = interquartile range; OS = overall survival; SD = standard deviation. 
a
One patient in each treatment group was enrolled but never treated. 
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Table 3 All Subsequent Postbaseline Antineoplastic Therapy Use for Metastatic 
Castration-Resistant Prostate Cancer in PREVAIL   
Parameter 
Nonvisceral Subgroup 
(n = 1513) 
Visceral Subgroup 
(n = 204) 
Enzalutamide  
(n = 774) 
Placebo  
(n = 739) 
Enzalutamide  
(n = 98) 
Placebo  
(n = 106) 
Patients with ≥ 1 postbaseline 
therapy listed below, n (%) 
307 (40) 516 (70) 44 (45) 78 (74) 
Antineoplastic therapy, n (%)     
Abiraterone acetate 157 (20) 340 (46) 22 (22) 45 (43) 
Cabazitaxel 40 (5.2) 93 (13) 11 (11)            17 (16) 
Docetaxel 255 (33) 412 (56) 31 (32)            67 (63) 
Enzalutamide 5 (0.6) 29 (3.9) 4 (4.1)             8 (7.5) 
Sipuleucel-T 11 (1.4) 7 (0.9) 1 (1.0)             3 (2.8) 
Patients taking ≥ 1 
investigational drug, n (%) 
38 (4.9) 69 (9.3) 4 (4.1)          12 (11) 
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Appendix 
 
Table A1 Summary of AEs in the PREVAIL Visceral Subgroup (Liver and Lung 
Subsets Combined) and Full Population 
Abbreviation: AE = adverse event. 
a
One patient in each treatment group was enrolled but never treated. 
 
b
At least 20% on enzalutamide and ≥ 2% more than placebo in the safety population. 
c
This seizure occurred after the data cutoff date. 
 
Parameter 
Visceral Subgroup, n (%) Full Study Population, n (%)
a
 
Enzalutamide 
(n = 98) 
Placebo 
(n = 106) 
Enzalutamide 
(n = 871) 
Placebo 
(n = 844) 
AE, n (%) 
Any AE  94 (96) 98 (93) 844 (97) 787 (93) 
Any grade 3-4 AE  47 (48) 38 (36) 374 (43) 313 (37) 
Any serious AE  35 (36) 33 (31) 279 (32) 226 (27) 
Most common AEs
b
 
Fatigue  28 (29) 26 (25) 310 (36) 218 (26) 
Back pain  25 (26) 24 (23) 235 (27) 187 (22) 
Constipation  26 (27) 20 (19) 193 (22) 145 (17) 
Arthralgia 17 (17) 12 (11) 177 (20) 135 (16) 
Specific AEs    
Hypertension  11 (11) 4 (3.8) 117 (13) 35 (4.1) 
Cardiac AEs  12 (12) 7 (6.6) 88 (10) 66 (7.8) 
Alanine aminotransferase 
elevation 
2 (2.0) 2 (1.9) 8 (0.9) 5 (0.6) 
Seizure 0 1 (0.9) 1 (0.1)
c
 1 (0.1) 
AE, event rate per 100 patient-years of exposure 
Fatigue  28.8 50.0 29.9 43.0 
Back pain 26.1 53.9 23.6 42.5 
Constipation 25.3 40.4 18.5 28.4 
Arthralgia 20.9 23.1 18.6 29.5 
Hypertension 11.3 7.7 10.8 6.6 
Cardiac disorders 19.2 15.4 10.3 14.8 
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Figure A1  PREVAIL CONSORT Diagram 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ITT, intent-to-treat. 
*Randomization was stratified by study site.  
†
Majority discontinued due to rising prostate-specific antigen. 
‡
Liver only or liver and lung metastases.  
Allocated to placebo (n = 845) 
- Received allocated intervention (n = 844) 
- Did not receive allocated intervention (n = 1) 
Assessed for eligibility  
(n = 2462) 
Randomized 1:1*  
(N = 1717) 
Lost to follow-up (n = 1) 
Discontinued intervention: 
- Death (n = 17, 1.9%) 
- Protocol violation (n = 1, 0.1%) 
- Patient withdrew consent (n = 21, 2.4%) 
- Disease progression (n = 355, 40.7%) 
- Adverse event (n = 49, 5.6%) 
- Other (n = 60, 6.9%)
†
 
 
Lost to follow-up (n = 0) 
Discontinued intervention: 
- Death (n = 7, 0.8%) 
- Patient withdrew consent (n = 40, 4.7%) 
- Disease progression (n = 577, 68.3%) 
- Adverse event (n = 51, 6.0%) 
- Other (n = 108, 12.8%)
†
 
 
Allocated to enzalutamide (n = 872) 
- Received allocated intervention (n = 871) 
- Did not receive allocated intervention (n = 1) 
Enrollment 
Screen failures 
(n = 745) 
ITT population (n = 845) 
- Nonvisceral subgroup (n = 739) 
- Visceral subgroup (n = 106) 
 Patients with liver metastases (n = 34)
‡
 
 Patients with lung metastases (n = 72) 
Safety population (n = 844) 
- Visceral subgroup (n = 106) 
 
ITT population (n = 872) 
- Nonvisceral subgroup (n = 774) 
- Visceral subgroup (n = 98) 
 Patients with liver metastases (n = 40)
‡
 
 Patients with lung metastases (n = 58) 
Safety population (n = 871) 
- Visceral subgroup (n = 98) 
-  
Allocation 
Analysis 
Follow-up 
 
 
 
 
Figure A2 Example of Complete Responses in metastatic Castration-Resistant 
Prostate Cancer Patients with a (A) Liver Lesion and (B) Lung Lesion at 
Baseline 
A 
 
B 
 
Abbreviation: PSA = prostate-specific antigen. 
 
 
 
